U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Go back to U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer| Gilead Sciences (NASDAQ: GILD) | Delayed: 143.72 -1.09 (0.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.81 | 52 Week High | $108.63 | |||
| Open | $145.24 | 52 Week Low | $71.39 | |||
| Day High | $145.99 | P/E | 79.40 | |||
| Day Low | $143.50 | EPS | $1.81 | |||
| Volume | 4,216,026 | |||||
